Por favor, use este identificador para citar o enlazar este ítem:http://uvadoc.uva.es/handle/10324/44628
Título
Cell culture-derived flu vaccine: Present and future
Año del Documento
2018
Editorial
Taylor & Francis
Descripción
Producción Científica
Documento Fuente
Human Vaccines & Immunotherapeutics, 2018, vol. 14, n. 8, p. 1874-1882
Abstract
The benefit of influenza vaccines is difficult to estimate due to the complexity of accurately assessing the burden of influenza. To improve the efficacy of influenza vaccines, vaccine manufacturers have developed quadrivalent influenza vaccine (QIV) formulations for seasonal vaccination by including both influenza B lineages. Three parallel approaches for producing influenza vaccines are attracting the interest of many vaccine manufacturing companies. The first and oldest is the conventional egg-derived influenza vaccine, which is used by the current licensed influenza vaccines. The second approach is a cell culture-derived influenza vaccine, and the third and most recent is synthetic vaccines. Here, we analyze the difficulties with vaccines production in eggs and compare this to cell culture-derived influenza vaccines and discuss the future of cell culture-derived QIVs.Keywords: Influenza vaccine, cell culture-derived, quadrivalent.
Materias Unesco
32 Ciencias Médicas
Palabras Clave
Vacuna
Influenza
ISSN
2164-5515
Revisión por pares
SI
Version del Editor
Propietario de los Derechos
© Taylor & Francis
Idioma
eng
Tipo de versión
info:eu-repo/semantics/publishedVersion
Derechos
openAccess
Collections
Files in this item
![Attribution-NonCommercial-NoDerivatives 4.0 Internacional](/themes/Mirage2//images/creativecommons/cc-by-nc-nd.png)